>
COMMANDS Global: GP Symbol: IBM FA
↑↓ Navigate Enter Open Esc Close ` Toggle

Summary

2.94 -0.46 (-13.53%) 08/14/2026
Aptevo Therapeutics Inc. (APVO)
Performance
Historical returns
1D
-13.53%
1W
-26.87%
1M
-36.36%
3M
-38.75%
6M
-58.88%
1Y
-91.99%
5Y
-100.00%
Snapshot
Key statistics
Close
2.94
Change
-0.46
Change %
-13.53%
Open
3.40
Day Range
2.84 – 3.40
Volume
79,258
Avg Vol (20d)
25,022
Rel Vol
3.17x
52W Range
2.84 - 48.78
vs 52W High
-93.97%
vs 52W Low
3.52%
Gap
-0.14
Market Cap
USD 8.42M
Beta
5.93
Price Chart
Advanced chartCompare
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Bull vs Bear
2 bullish · 4 bearish points
Bullish view
  • The Aug 2026 quarter beat on EPS by $0.70 (11.6% above consensus).
  • Trades at just 0.2× the 2030 consensus EPS of $16.29.
Bearish view
  • Missed consensus EPS in 5 of the last 8 quarters.
  • Trades 68.0% below its 200-day average, a downtrend still intact.
  • Still 92.1% below its 52-week high of $37.26.
  • Lagged the S&P 500 by 42.8% over the last quarter (-38.8% against +4.0%).
Both sides are generated from reported financials, consensus estimates, analyst targets and the price series — not from opinion.
Notable Price Movement
Historical returns
Aug 14
2026
$2.94 13.53%LatestEarnings52W Low
Aptevo Therapeutics fell 13.53% to $2.94, a 3.1σ move against its 60-day volatility, on 3.5× average volume. This was largely stock-specific: the S&P 500 fell 0.20% while Healthcare peers (XLV) fell 0.60% that session, leaving about 12.9 points of the move unexplained by its sector. Shares closed near the session low (18% of the day's range), set a 52-week closing low and marked a 3rd consecutive decline. This was the first session after quarterly results: EPS of $-5.31 vs $-6.01 expected (a beat). The move left the stock 92.1% below its 52-week high.
Aug 13
2026
$3.40 2.86%Earnings52W Low
Aptevo Therapeutics fell 2.86% to $3.40, on 1.4× average volume. This was largely stock-specific: the S&P 500 gained 0.70% while Healthcare peers (XLV) fell 0.04% that session, leaving about 2.8 points of the move unexplained by its sector. Shares opened with a 2.86% gap down and set a 52-week closing low. It came 3 sessions after the Q2 2026 print.
Aug 12
2026
$3.50 15.38%Earnings52W Low
Aptevo Therapeutics fell 15.38% to $3.50, its biggest one-day drop in 5 months and a 3.9σ move against its 60-day volatility, on 8.6× average volume. This was largely stock-specific: the S&P 500 gained 0.25% while Healthcare peers (XLV) rose 0.26% that session, leaving about 15.6 points of the move unexplained by the market. Shares opened with a 2.80% gap down, closed near the session low (0% of the day's range) and set a 52-week closing low. It came 2 sessions after the Q2 2026 print. Historically, after 2.5σ-or-larger down days, Aptevo Therapeutics returned -9.13% on average over the following 5 sessions (40% positive, n=15).
Aug 11
2026
$4.14 2.89%Earnings
Aptevo Therapeutics rose 2.89% to $4.14, though on light volume (0.2× the 20-day average). This was largely stock-specific: the S&P 500 fell 0.32% while Healthcare peers (XLV) fell 0.26% that session, leaving about 3.1 points of the move unexplained by its sector. Shares opened with a 1.50% gap up and closed near the session high (87% of the day's range). It came 1 session after the Q2 2026 print.
Aug 10
2026
$4.02 3.83%Earnings
Aptevo Therapeutics fell 3.83% to $4.02, though on light volume (0.6× the 20-day average). This was largely stock-specific: the S&P 500 gained 0.01% while Healthcare peers (XLV) rose 1.84% that session, leaving about 3.8 points of the move unexplained by the market. Shares opened with a 1.61% gap down and closed near the session low (6% of the day's range). This was the first session after Q2 2026 results.
Jul 21
2026
$4.42 7.05%
Aptevo Therapeutics fell 7.05% to $4.42, a 1.8σ move against its 60-day volatility, though on light volume (0.3× the 20-day average). This was largely stock-specific: the S&P 500 gained 0.83% while Healthcare peers (XLV) rose 0.63% that session, leaving about 7.7 points of the move unexplained by its sector. Shares opened with a 3.05% gap down, closed near the session low (17% of the day's range) and lost their 20- and 50-day moving averages.
Computed from adjusted closes over the last 22 sessions; attribution vs SPY and XLV.
Price Performance
All periods
PeriodPeriod LowPeriod HighPerformance
1-Month2.84 +3.52%
on 08/14/26
Open 4.50
4.90 -40.00%
on 07/17/26
-1.56 (-34.67%)
since 07/16/26
3-Month2.84 +3.52%
on 08/14/26
Open 4.80
5.47 -46.25%
on 06/03/26
-1.86 (-38.75%)
since 05/14/26
6-Month2.84 +3.52%
on 08/14/26
Open 6.59
7.70 -61.82%
on 02/17/26
-3.65 (-55.39%)
since 02/12/26
YTD2.84 +3.52%
on 08/14/26
Open 9.39
10.70 -72.52%
on 01/20/26
-6.45 (-68.69%)
since 01/02/26
52-Week2.84 +3.52%
on 08/14/26
Open 34.38
48.78 -93.97%
on 09/16/25
-31.44 (-91.45%)
since 08/13/25
5-Year2.84 +3.52%
on 08/14/26
Open 11,041,747.00
12,940,646.00 -100.00%
on 11/23/21
-11,041,744.06 (-100.00%)
since 08/06/21
New Highs
Historical highs
5-Day
1×
-28.92% from peak
1-Month
1×
-38.17% from peak
3-Month
2×
-43.89% from peak
6-Month
3×
-60.00% from peak
YTD
2×
-70.09% from peak
52-Week
1×
-92.11% from peak
2-Year
2×
-99.95% from peak
3-Year
1×
-100.00% from peak
5-Year
2×
-100.00% from peak
10-Year
16×
-100.00% from peak
Financial SnapshotFY 2025
Full financials
Revenue
n/a
Net Income
-USD 25.97M
+7.6% YoY
EPS
-87.27
-95.0% YoY
Gross Margin
n/a
Operating Margin
n/a
Net Margin
n/a
EBITDA
-USD 25.73M
Free Cash Flow
-USD 25.59M
ROE
-149.4%
ROA
-95.5%
Debt / Equity
0.27x
net debt -USD 16.99M
Cash & Equiv.
USD 21.62M
News
All news
08/14 08:05 ET · accessnewswire.com
Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results
Mipletamig Drives Clinical Momentum with Strong Frontline AML Data, Path Toward Phase 2 Chief Scientific Officer Appointment Strengthens Execution Across Advancing Oncology Pipeline Non-Dilutive Grant Funding Advances APVO451 and Validates Trispecific Solid Tumor Strategy Strategic Niowave...
08/13 16:05 ET · accessnewswire.com
Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds
SEATTLE, WA / ACCESS Newswire / August 13, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today closed its previously announced warrant inducement transaction with certain...
08/12 09:30 ET · accessnewswire.com
Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds
SEATTLE, WA / ACCESS Newswire / August 12, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced it has entered into warrant inducement letter agreements with...
07/27 08:05 ET · accessnewswire.com
Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone
Filing supports potential development of radiopharmaceuticals, T-cell engagers and other immune-based approaches using a versatile platform approach SEATTLE, WA / ACCESS Newswire / July 27, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel...
06/30 08:05 ET · accessnewswire.com
Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors
SEATTLE, WA / ACCESS Newswire / June 30, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced it has been awarded a $1.5...
05/28 08:05 ET · accessnewswire.com
Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D.
Experienced oncology R&D leader appointed to support Aptevo's expanding oncology pipeline and new radiopharmaceutical development strategy SEATTLE, WA / ACCESS Newswire / May 28, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel immuno-oncology...
05/27 08:05 ET · accessnewswire.com
Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing
50/50 Strategic Collaboration Will Develop Up to Three Radiopharmaceutical Programs Innovation and Investment Continue to Accelerate Across Radiopharmaceutical Oncology SEATTLE, WA AND LANSING, MI / ACCESS Newswire / May 27, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage...
05/20 13:01 ET · zacks.com
All You Need to Know About Aptevo Therapeutics (APVO) Rating Upgrade to Buy
Aptevo Therapeutics (APVO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Market News ×
Loading news…